NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts describing the company's PAK4 allosteric modulators (PAMs) have been selected for presentation at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) taking place April 18-22 in Philadelphia. These preclinical abstracts, which represent both company and investigator-sponsored research, present data related to intercellular PAMs effects on K-Ras and WNT/ß-catenin signaling pathways and the characterization of single agent antitumor activity. Detailed results from these studies will be presented at the conference.
"We are pleased to be presenting updated research on Karyopharm's PAK4 allosteric inhibitors at the AACR annual meeting," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "Presentations on our PAK4 inhibitors include effects on key signaling pathways along with activity in several solid tumor models, supporting further development of these novel oral PAMs."
Abstracts related to Karyopharm's novel, selective, oral small-molecule PAMs include:
|- Oral Presentation: Overcoming drug resistance and stemness in oncogenic K-Ras driven pancreatic ductal adenocarcinoma through PAK4 inhibition|
|Author:||Azmi, Wayne State University|
|Session:||MS.ET06.01. Exploiting the MAPK Pathway in Cancer|
|Date/Time:||Tuesday, April 21, 3:20 - 3:35 PM|
|- Poster Title: Novel PAK4 allosteric modulators (PAMs) provide potential therapeutic options in human gastric cancer|
|Author:||Chien, Cancer science institute of Singapore|
|Session:||PO.MCB04.02. Kinases and Inhibitors|
|Date/Time:||Sunday, April 19, 1:00 - 5:00 PM|
|- Poster Title: Inhibition of PAK4 attenuates renal cell carcinoma (RCC) growth|
|Author:||Abu Aboud, UC Davis|
|Session:||PO.ET07.02. Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy|
|Date/Time:||Monday, April 20, 1:00 - 5:00 PM|
|- Poster Title: Inhibition of PAK4 blocks growth of breast cancer cells|
|Author:||Rane, Rutgers University|
|Session:||PO.MCB01.06. Tumor Cell-Stromal and Cell-Cell Interactions|
|Date/Time:||Tuesday, April 21, 1:00 - 5:00 PM|
|- Poster Title: PAK4 allosteric modulators (PAMs) repress the Wnt/ß-catenin signaling pathway and tumor growth|
|Session:||PO.ET06.07. Kinase Inhibitors and Other Targets|
|Date/Time:||Wednesday, April 22, 8:00 AM - 12:00 PM|
P21-Activated Kinase 4 (PAK4) is a member of the PAK family of proteins that regulate cell survival, cell division and apoptosis. PAK4 is a key downstream effector of the K-Ras pathway and mediates cell motility, proliferation, and survival. Karyopharm has identified selective, novel, orally-bioavailable small molecule PAK4 allosteric modulators (PAMs) with demonstrated anti-tumor activity both in vitro and in vivo. Karyopharm's lead PAMs have shown promising results in many preclinical models for the treatment of a wide variety of cancers.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). SINE™ compounds have also shown biological activity in models of cancer, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE™ compounds, including Selinexor (KPT-330) or any PAK4 inhibitor, or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission (SEC) as of March 13, 2015. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.